Pharmaceutical company AGI Therapeutics has announced preliminary results from second phase trials of two of its treatments.
The company said results for arverapamil, which is aimed at patients suffering from irritable bowel syndrome (IBS), were positive. AGI said the data provided 'a compelling case' for moving the treatment into clinical development.
AGI said results for espindolol, which is targeted at dyspepsia, were less conclusive. Espindolol is part of a separate trial for the treatment of IBS.
